Satellos Bioscience (MSLE) Non-Current Assets (2023 - 2026)

Satellos Bioscience (MSLE) posted quarterly Non-Current Assets of $8000.0 for Q1 2026, up 60.0% quarter-over-quarter from $5000.0 in Q4 2025.

Satellos Bioscience (MSLE) Non-Current Assets (2023 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has reported Non-Current Assets for 4 consecutive years, with $8000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Assets changed N/A year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $2.9 million (changed N/A YoY), while the FY2025 annual figure was $5000.0, up 39.69% from the prior year.
Non-Current Assets grew to $8000.0 in Q1 2026 per MSLE's latest filing, from $5000.0 in the prior quarter.
Across five years, Non-Current Assets topped out at $2.9 million in Q4 2023 and bottomed at $3579.2 in Q4 2024.
Historically, Non-Current Assets has averaged $734273.1 across 4 years, with a median of $6500.0 in 2025.
Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 99.88% — and 2025, when it soared 39.69%.
Satellos Bioscience's Non-Current Assets stood at $2.9 million in 2023, then sank by 99.88% to $3579.2 in 2024, then soared by 39.69% to $5000.0 in 2025, then soared by 60.0% to $8000.0 in 2026.
Business Quant data shows MSLE's Non-Current Assets at $8000.0 in Q1 2026, $5000.0 in Q4 2025, and $3579.2 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.96 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	938.60 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	468.65 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	18.06 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	6.80 Bn
10	Satellos Bioscience	208.31 Mn	208.31 Mn	-	7,000.00

Download Data